Oragenics receives NYSE delisting notice for equity shortfall; ONP-002 Phase 2 trial planned Q4 2024

ORAGENICS INC

NYSE American notified Oragenics it is not in compliance with Section 1003(a)(i) (stockholders' equity <$2M); compliance plan approved, deadline Oct 18, 2025.
ONP-002 cleared FDA-required cardiotoxicity and genotoxicity tests; Phase 2 trial expected to start Q4 2024 in Australia.
Improved intranasal formulation increases ONP-002 per dose by 4X; automated device prototype for use in acute concussion completed.
Closed public offering raising ~$1.1M to fund ONP-002 development and corporate needs.
Appointed Dr. Peacock as Chief Clinical Officer and Dr. Kelly as Chief Medical Officer for Phase 2 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.